Nuvectis Pharma, Inc.
NVCT
$18.96
-$0.27-1.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -27.85M | -27.16M | -26.44M | -25.38M | -22.07M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.49M | 6.51M | 6.03M | 5.70M | 5.40M |
| Change in Net Operating Assets | 1.84M | 2.30M | 4.40M | 5.18M | 4.26M |
| Cash from Operations | -19.51M | -18.35M | -16.01M | -14.50M | -12.41M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.37M | 14.42M | 31.21M | 34.92M | 22.87M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -493.00K | -807.00K | -2.10M | -2.14M | -1.79M |
| Cash from Financing | 14.88M | 13.61M | 29.11M | 32.77M | 21.09M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.63M | -4.73M | 13.10M | 18.27M | 8.68M |